Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Control of Metastases via Myeloid CD39 and NK Cell Effector Function.

Yan J, Li XY, Roman Aguilera A, Xiao C, Jacoberger-Foissac C, Nowlan B, Robson SC, Beers C, Moesta AK, Geetha N, Teng MWL, Smyth MJ.

Cancer Immunol Res. 2020 Jan 28. doi: 10.1158/2326-6066.CIR-19-0749. [Epub ahead of print]

PMID:
31992567
2.

Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.

Li XY, Moesta AK, Xiao C, Nakamura K, Casey M, Zhang H, Madore J, Lepletier A, Aguilera AR, Sundarrajan A, Jacoberger-Foissac C, Wong C, Dela Cruz T, Welch M, Lerner AG, Spatola BN, Soros VB, Corbin J, Anderson AC, Effern M, Hölzel M, Robson SC, Johnston RL, Waddell N, Smith C, Bald T, Geetha N, Beers C, Teng MWL, Smyth MJ.

Cancer Discov. 2019 Dec;9(12):1754-1773. doi: 10.1158/2159-8290.CD-19-0541. Epub 2019 Nov 7.

PMID:
31699796
3.

Optimization of peptide-based cancer vaccine compositions, by sequential screening, using versatile liposomal platform.

Jacoberger-Foissac C, Saliba H, Seguin C, Brion A, Kakhi Z, Frisch B, Fournel S, Heurtault B.

Int J Pharm. 2019 May 1;562:342-350. doi: 10.1016/j.ijpharm.2019.03.002. Epub 2019 Mar 15.

PMID:
30880104

Supplemental Content

Loading ...
Support Center